secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001062822-24-000032
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon amends Oxford loan: interest-only period to May 2027, maturity to March 2029
--------------------------------------------------------------------------------

- Amortization date extended to May 1, 2027; maturity date extended to March 1, 2029.
- Final payment percentage increased from prior amount to 7.00% of outstanding principal.
- New financial covenant: minimum cash at 50% of outstanding Term Loans through June 30, 2026.
- Minimum trailing 6-month net product revenue tied to sNDA approval of sotagliflozin in CKD by March 31, 2025.
- Amendment fee paid; existing loan agreement continues in full force except as amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000032/0001062822-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000032/lxrx-20240628.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer